Monographie - Tigecycline - Stabilis 4.0

Poslední aktualizace :
19/11/2024

Antibiotikas

Tigecycline

Įpurškimas

Tirpalų stabilumas

Mišinių stabilumas

Stabilumą lemiantys veiksniai

Suderinamumas

Leidimo būdai

Bibliografija

pdf

Cheminė sandara

Prekinis pavadinimas

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eticina	Meksikas
Grexyl	Meksikas
Linicetil	Meksikas
Mrsacin	Turkija
Tecygen	Čilė
Tigecid	Turkija
Tigecilina	Argentina, Čilė, Ekvadoras
Tigecycline	Kanada
Tigetop	Čilė
Tizoxim	Argentina
Tygacil	Airija, Argentina, Austrija, Belgija, Čilė, Danija, Didžioji Britanija, Ekvadoras, Graikija, Islandija, Ispanija, Italija, Japonija, Jungtinės Amerikos Valstijos, Jungtiniai Arabų Emyratai, Kanada, Kolumbija, Lenkija, Liuksemburgas, Malaizija, Meksikas, Naujojoje Zelandijoje, Norvegija, Olandija, Peru, Portugalija, Prancūzija, Rumunija, Saudo Arabija, Suomija, Švedija, Šveicarija, Turkija, Venesuela, Vengrija, Vokietija
Zomiprerin	Peru

Bibliografija

Įpurškimas

Bibliografija : Tigecycline

	tipas	leidinys
2262	Žurnalas	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratorija	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Žurnalas	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorija	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratorija	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratorija	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratorija	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	plakatas	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakatas	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakatas	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Žurnalas	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Žurnalas	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Žurnalas	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Žurnalas	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Žurnalas	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales